Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
51.68
USD
|
+0.98%
|
|
-1.28%
|
-17.69%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,808
|
19,048
|
16,213
|
17,869
|
14,072
|
11,604
|
-
|
-
|
Enterprise Value (EV)
1 |
16,742
|
17,535
|
13,865
|
14,630
|
10,416
|
7,231
|
5,927
|
4,365
|
P/E ratio
|
42.6
x
|
-64
x
|
17.2
x
|
52.8
x
|
23.7
x
|
15.1
x
|
11.9
x
|
9.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.71
x
|
7.14
x
|
5.43
x
|
5.26
x
|
3.81
x
|
2.81
x
|
2.53
x
|
2.29
x
|
EV / Revenue
|
7.76
x
|
6.58
x
|
4.64
x
|
4.31
x
|
2.82
x
|
1.75
x
|
1.29
x
|
0.86
x
|
EV / EBITDA
|
36.7
x
|
-82.8
x
|
21.5
x
|
24.5
x
|
14.8
x
|
6.93
x
|
4.37
x
|
2.51
x
|
EV / FCF
|
26.5
x
|
-56.2
x
|
24.4
x
|
16.4
x
|
22.4
x
|
7.96
x
|
5.3
x
|
3.2
x
|
FCF Yield
|
3.78%
|
-1.78%
|
4.1%
|
6.1%
|
4.45%
|
12.6%
|
18.9%
|
31.3%
|
Price to Book
|
7.22
x
|
7.26
x
|
4.32
x
|
4.09
x
|
2.71
x
|
1.83
x
|
1.52
x
|
1.26
x
|
Nbr of stocks (in thousands)
|
215,397
|
218,996
|
220,891
|
222,475
|
224,109
|
224,526
|
-
|
-
|
Reference price
2 |
87.32
|
86.98
|
73.40
|
80.32
|
62.79
|
51.68
|
51.68
|
51.68
|
Announcement Date
|
13/02/20
|
09/02/21
|
08/02/22
|
07/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,159
|
2,667
|
2,986
|
3,395
|
3,696
|
4,127
|
4,590
|
5,058
|
EBITDA
1 |
456.5
|
-211.9
|
643.6
|
597.7
|
703.2
|
1,043
|
1,355
|
1,738
|
EBIT
1 |
402
|
-263.7
|
585.8
|
579.4
|
620.5
|
1,120
|
1,444
|
1,763
|
Operating Margin
|
18.62%
|
-9.89%
|
19.62%
|
17.07%
|
16.79%
|
27.13%
|
31.45%
|
34.85%
|
Earnings before Tax (EBT)
1 |
486.8
|
-232.2
|
570.4
|
529.1
|
834.2
|
1,064
|
1,320
|
1,712
|
Net income
1 |
446.9
|
-295.7
|
948.6
|
340.7
|
597.6
|
797.2
|
990.6
|
1,220
|
Net margin
|
20.7%
|
-11.09%
|
31.76%
|
10.04%
|
16.17%
|
19.31%
|
21.58%
|
24.13%
|
EPS
2 |
2.050
|
-1.360
|
4.270
|
1.520
|
2.650
|
3.418
|
4.329
|
5.301
|
Free Cash Flow
1 |
632.6
|
-312
|
568.5
|
892.1
|
464
|
908.6
|
1,118
|
1,366
|
FCF margin
|
29.3%
|
-11.7%
|
19.04%
|
26.28%
|
12.56%
|
22.02%
|
24.35%
|
27.01%
|
FCF Conversion (EBITDA)
|
138.56%
|
-
|
88.33%
|
149.27%
|
65.99%
|
87.14%
|
82.47%
|
78.58%
|
FCF Conversion (Net income)
|
141.55%
|
-
|
59.93%
|
261.88%
|
77.64%
|
113.99%
|
112.82%
|
111.93%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/20
|
09/02/21
|
08/02/22
|
07/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
813
|
862.9
|
733.2
|
911.4
|
823.3
|
926.7
|
808.7
|
954.6
|
919
|
1,013
|
927.7
|
1,025
|
1,052
|
1,111
|
1,087
|
EBITDA
1 |
250.1
|
125.6
|
-
|
270.9
|
155.1
|
137.9
|
-
|
214.1
|
236.1
|
-
|
213
|
313
|
327
|
309
|
-
|
EBIT
1 |
235.4
|
110.7
|
116.5
|
254.4
|
138.4
|
70.09
|
24.77
|
193.8
|
214.7
|
187.3
|
208.5
|
293.5
|
316.1
|
314.3
|
356.1
|
Operating Margin
|
28.96%
|
12.83%
|
15.89%
|
27.92%
|
16.81%
|
7.56%
|
3.06%
|
20.3%
|
23.36%
|
18.48%
|
22.47%
|
28.64%
|
30.05%
|
28.29%
|
32.75%
|
Earnings before Tax (EBT)
1 |
209.5
|
120
|
70.54
|
229.4
|
148.6
|
80.62
|
51.86
|
277.6
|
233.8
|
271
|
197.9
|
283.8
|
287.7
|
331.3
|
-
|
Net income
1 |
181.7
|
563.9
|
37.99
|
161.4
|
112.8
|
28.46
|
21.7
|
203.5
|
171.3
|
201.1
|
131.6
|
200.2
|
209.4
|
236.1
|
-
|
Net margin
|
22.35%
|
65.35%
|
5.18%
|
17.71%
|
13.7%
|
3.07%
|
2.68%
|
21.32%
|
18.64%
|
19.84%
|
14.19%
|
19.53%
|
19.9%
|
21.25%
|
-
|
EPS
2 |
0.8200
|
2.540
|
0.1700
|
0.7200
|
0.5000
|
0.1300
|
0.1000
|
0.9000
|
0.7600
|
0.8900
|
0.5902
|
0.8685
|
0.8818
|
0.9416
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/11/21
|
08/02/22
|
03/05/22
|
02/08/22
|
01/11/22
|
07/02/23
|
02/05/23
|
01/08/23
|
31/10/23
|
13/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,067
|
1,513
|
2,348
|
3,239
|
3,656
|
4,373
|
5,677
|
7,239
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
633
|
-312
|
568
|
892
|
464
|
909
|
1,118
|
1,366
|
ROE (net income / shareholders' equity)
|
27.2%
|
-11.4%
|
29.7%
|
8.37%
|
12.5%
|
17%
|
18.2%
|
18.8%
|
ROA (Net income/ Total Assets)
|
20.3%
|
-8.46%
|
22.3%
|
6.32%
|
9.47%
|
14.7%
|
14.8%
|
14.9%
|
Assets
1 |
2,205
|
3,494
|
4,247
|
5,387
|
6,312
|
5,408
|
6,674
|
8,177
|
Book Value Per Share
2 |
12.10
|
12.00
|
17.00
|
19.60
|
23.10
|
28.20
|
34.00
|
41.20
|
Cash Flow per Share
2 |
3.270
|
-0.5700
|
3.370
|
4.330
|
2.200
|
4.400
|
4.720
|
-
|
Capex
1 |
78.1
|
187
|
181
|
77.8
|
32.5
|
140
|
123
|
142
|
Capex / Sales
|
3.62%
|
7.03%
|
6.06%
|
2.29%
|
0.88%
|
3.39%
|
2.67%
|
2.8%
|
Announcement Date
|
13/02/20
|
09/02/21
|
08/02/22
|
07/02/23
|
13/02/24
|
-
|
-
|
-
|
Last Close Price
51.68
USD Average target price
75.2
USD Spread / Average Target +45.51% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.69% | 11.6B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -43.00% | 11.51B | | -9.14% | 11.95B | | +5.24% | 8.71B | | -8.42% | 8.12B | | +2.29% | 7.72B |
Biopharmaceuticals
|